Quantcast

Latest Vaccination Stories

2014-07-01 04:21:50

ZURICH-SCHLIEREN, Switzerland, July 1, 2014 /PRNewswire/ -- GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced the initiation of a Phase 1 clinical trial of a candidate vaccine to prevent infections caused by Extra-intestinal Pathogenic Escherichia coli (ExPEC), such as urinary tract infections (UTIs). The investigational vaccine is being co-developed by GlycoVaxyn AG and Janssen Pharmaceuticals Inc. (Janssen), one of the Janssen...

2014-06-30 12:29:20

Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group BURLINGTON, Mass., June 30, 2014 /PRNewswire/ -- Decision Resources Group finds that the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8 percent annual growth) in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This impressive...

2014-06-27 12:26:58

ChinaMarketResearchReports.com adds Latest Report on "China Animal Vaccine Industry Report, 2013-2016" to its store. DALLAS, June 27, 2014 /PRNewswire-iReach/ -- Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. Europe and the United States and other developed countries are the main force of traditional animal vaccine markets in the world, still taking around 60% nowadays. In recent years, European and American...

2014-06-25 10:12:46

BMJ-British Medical Journal Research: Whooping cough in school age children presenting with persistent cough in UK primary care after introduction of the preschool pertussis booster vaccination: prospective cohort study Whooping cough has been found in a fifth of UK school age children visiting their doctor with a persistent cough, even though most have been fully vaccinated, finds a study published on bmj.com today. Before the preschool pertussis booster vaccination had been...

2014-06-23 23:10:50

Andrea Seratte, Executive Vice President of TransactRx will be presenting at the annual NACCHO conference held in Atlanta, GA July 8th – 10th. Mrs. Seratte will be presenting on the topic: Building Public Health Capacity Through the Provision Vaccination Programs Through the Use of Innovative Technology, along with Neal Lustig, BS, MPH, Director of Health of the Pomperaug District Department of Health (PDDH). Coral Gables, FL (PRWEB) June 23, 2014 Andrea Seratte, Executive Vice...

2014-06-23 12:29:48

PARIS, June 23, 2014 /PRNewswire/ -- OSE Pharma SA receives a positive agreement to initiate a Phase 3 clinical trial with OSE-2101, a therapeutic cancer vaccine for non-small cell lung cancer (NSCLC) OSE Pharma SA, a European cancer immunotherapy company with a specific T cytotoxic technology, today announced that it has received positive feedback from an end of Phase 2 / Pre-Phase 3 meeting with the U.S. Food and Drug Administration (FDA) and Scientific Advice from...

2014-06-23 04:20:45

Inovio's Immunotherapy will Treat Women with Inoperable HPV-caused Cancer BLUE BELL, Pa., June 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. INO-3112 is a combination of Inovio's lead active immunotherapy...

2014-06-18 16:26:28

Breaking New Ground in a Collective Search for Vaccines against Major Killer Diseases NEW YORK, June 18, 2014 /PRNewswire-USNewswire/ -- New technologies and insights in antigen discovery, genomics and immunological monitoring offer tremendous potential that could be collectively leveraged to speed development of vaccines against major diseases, according to leading scientists who met across specializations to explore creation of a Human Vaccines Project and reported their...

2014-06-17 12:29:52

ZUG, Switzerland, June 17, 2014 /PRNewswire/ -- Swiss-based AmVac AG, a private biotech company focused on the development of innovative vaccines, announced today the initiation of a Phase III study with AmVac's lead vaccine Gynevac in Bacterial Vaginosis (BV). The trial aims to confirm the safety and efficacy of a new generation of the vaccine produced in accordance to the current GMP standards. The previous version, containing Thiomersal, had been approved in Hungary in 1997...

2014-06-17 12:28:42

MERIDEN, Conn., June 17, 2014 /PRNewswire/ -- Protein Sciences Corporation announced today that BARDA, within the U.S. Department of Health and Human Services, exercised Option Period 2 of its contract with the Company (contract number HHS0100200900106C) to support development, scale-up and expanded licensure of the Company's influenza vaccines, Flublok® (seasonal) and Panblok® (pandemic). Option Period 2 has a budget of $50.6 million and will run through December 31, 2015. The...


Latest Vaccination Reference Libraries

0_ac8af9115d7f37daaaa2af4dba273fb1
2011-01-11 14:17:29

The Cowpox virus causes a skin disease known as cowpox. It is related to the vaccinia virus and gained its name because it spread by dairymaids touching the udders of infected cows. It manifests as red blisters. It is similar to smallpox although much milder and was actually the basis of the first smallpox vaccine. A person who recovers from cowpox is immune to smallpox. In 1980 the World Health Organization announced that smallpox was the first disease to be eradicated world wide by a...

More Articles (1 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.